Kidney transplant recipients who had nonfatal MACE within the first year after transplant surgery, compared with those who did not, had a significantly lower 1-year survival rate (80.5% vs 97.4%).
How outcomes differ between recipients of deceased vs living donor kidneys of advanced age needs to be studied further.
Although valganciclovir is an effective CMV prophylactic agent after kidney transplantation, it is associated with significant side effects.
Effective therapy of post-transplant membranous nephropathy may improve outcomes.
The current US Kidney Allocation System (KAS) may disadvantage waitlist candidates already receiving dialysis, according to investigators.
In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.
A growing body of research supports harvesting and transplanting of donor acute kidney injury kidneys.
The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.
Performing dual deceased donor kidney transplantations may maximize use of suboptimal kidneys, according to investigators.
Recent organ allocation changes have increased travel and subsequent cold ischemia times of kidney allografts.